8-OHdG & mtDNA Biomarkers in Aging, MCI, Alzheimer’s & Parkinson’s Disease 切換：本地版 ↗

1Background: Mitochondrial Oxidative Stress in Neurodegeneration

核心生物標記Moderate

Mitochondrial DNA (mtDNA) is ~10× more susceptible to oxidative damage than nuclear DNA. The resulting lesion — 8-OHdG — accumulates with aging and is amplified in AD and PD. Damaged mtDNA activates the cGAS-STING axis, driving neuroinflammation shared across both diseases.

~80Records identified
48Quality filter ≥2016/landmark
42Included in review

Mitochondria generate the majority of cellular ROS via oxidative phosphorylation. 8-hydroxy-2′-deoxyguanosine (8-OHdG) is formed when hydroxyl radicals attack guanine in both nuclear and mitochondrial DNA. mtDNA is particularly vulnerable: no histone protection, adjacent to the electron transport chain, limited base-excision repair.[1][2]

The mitochondrial cascade hypothesis of AD posits that bioenergetic failure precedes Aβ accumulation and tau hyperphosphorylation. In PD, Complex I deficiency and impaired PINK1/Parkin mitophagy establish mtDNA integrity as central to dopaminergic vulnerability. The cGAS-STING pathway bridges mitochondrial injury to NF-κB-mediated neuroinflammation in both diseases.[3][4]

重點整理mtDNA 缺乏組蛋白保護且緊鄰電子傳遞鏈，8-OHdG 是最主要的氧化損傷標記。cGAS-STING 通路被胞漿損傷 mtDNA 活化後驅動 NF-κB → 神經炎症，在 AD 與 PD 中共用此上游機制。

28-OHdG as an Oxidative DNA Damage Biomarker

2.1 Measurement & Specimen Considerations

8-OHdG is quantified by ELISA, LC-MS/MS, or HPLC-ECD. A 2020 SR&MA (84 studies) confirmed urinary 8-OHdG as a reliable, reproducible oxidative stress biomarker.[5] Specimen hierarchy: CSF (most CNS-specific, invasive) > urine (creatinine-normalised, non-invasive) > plasma (sensitive to pre-analytical variation).

2.2 Normal Aging

GRADE 證據確定性：⊕⊕⊝⊝ Low Consistent direction; limited longitudinal data

CSF 8-OHdG correlates positively with age in healthy individuals.[6] Urinary 8-oxoGsn may reflect biological age and predict age-associated disease risk.[7]

2.3 MCI

GRADE 證據確定性：⊕⊕⊝⊝ Low Mostly cross-sectional; small samples

StudySpecimenFindingGRADE
Oxidative Stress in Preclinical MCI (2025)Plasma↑ 8-OHdG in MCI vs CN; sex- and age-stratified effects[47]Low
Correa et al. 2024 PMC 11287840Plasma8-OHdG correlated with CSF Aβ42/40 and NfL; higher 8-OHdG → greater amyloid burden[45]Low

2.4 Alzheimer's Disease

GRADE 證據確定性：⊕⊕⊕⊝ Moderate Multiple independent cohorts; meta-analytic support

SourceSpecimenKey FindingGRADE
Liu et al. 2016 PMC 4913710Plasma8-OHdG higher in AD vs controls (p<0.001); antioxidant capacity simultaneously reduced[9]Moderate
Review of oxidative stress in early AD PMC 8543250Lymphocytes/Serum8-oxo2dG accumulates early in AD; elevated in peripheral lymphocytes and serum[11]Moderate
8-OHdG + frailty in ADUrineUrinary 8-OHdG correlated with physical frailty scores, CRP and IL-6[12]Low
APOE4 + ChEI cohort PMC 8750673BloodAPOE4 carriers: further elevated oxidative stress + lower mtDNA-CN; ChEI therapy partially reversed both[14]Low

2.5 Parkinson's Disease

GRADE 證據確定性：⊕⊕⊕⊝ Moderate Meta-analytic support; treatment confounders limit disease specificity

SourceSpecimenKey FindingGRADE
Kikuchi et al. 2002 (classic) Neurology ↗Urine8-OHdG elevated in PD vs controls; progressive increase with H&Y stage[15]Moderate
Rani et al. SR&MA 2019 PMC 6420691BloodBlood 8-OHdG elevated in PD; pooled SMD positive, moderate heterogeneity[17]Moderate
Oxidative Stress in PD SR&MA 2018 PMC 6041404Multiple8-oxo-dG, MDA, LPO all elevated in PD; 8-oxo-dG most consistent[18]Moderate
Disease Specificity CaveatUrinary 8-OHdG similarly elevated in MSA — limiting utility for differential diagnosis within parkinsonism spectrum.
Take-Home8-OHdG elevated in AD and PD across plasma, urine, CSF, saliva. In-house data (Hank lab): AD > control AND AD > PDD — differential mtDNA repair capacity between dementias.

3Mitochondrial DNA Copy Number (mtDNA-CN)

核心生物標記Moderate

Blood leukocyte mtDNA-CN declines with aging and is further reduced in both AD and PD. In AD the effect is stronger in females. In PD, lower mtDNA-CN predicts future PDD — first prospective prognostic finding.

mtDNA-CN proxies mitochondrial biogenesis, regulated by PGC-1α, TFAM, and NRF1. Key caveat: platelet count, anticoagulant type, leukocyte differential, and reference gene choice all substantially affect qPCR estimates.[20]

3.1 Aging & MCI

GRADE 證據確定性：⊕⊕⊝⊝ Low Cross-sectional; cell-composition confounders

mtDNA-CN declines progressively with biological aging. A meta-analysis showed lower mtDNA-CN associated with smaller brain volumes, worse white matter integrity, and poorer cognition.[8] Reduced blood mtDNA-CN is detectable in MCI, concurrent with D-loop CpG hypermethylation.[21][22]

3.2 Alzheimer's Disease

GRADE 證據確定性：⊕⊕⊕⊝ Moderate 13/15 case-control studies consistent direction; sex-specific mechanism

SourceSampleKey FindingGRADE
Literature SR (13/15 studies)BloodLower blood mtDNA-CN in AD vs controls — consistent across case-control studiesModerate
Alzheimer's Res Ther 2024 doi ↗BloodmtDNA-CN correlates with CSF Aβ42/40, t-Tau, p-Tau, plasma NfL in females specifically[46]Moderate
APOE4 cohort PMC 8750673BloodLower mtDNA-CN in APOE4+ AD; ChEI therapy partially reverses deficit[14]Low
Longitudinal D-loop study 2026BloodLongitudinal ↑ D-loop methylation + ↓ mtDNA-CN tracks AD staging[49]Low

3.3 Parkinson's Disease

GRADE 證據確定性：⊕⊕⊕⊝ Moderate Consistent direction; emerging prospective data; immune confounding

SourceSampleKey FindingGRADE
Bose & Bhatt 2016 PMID 26639155Blood + SNReduced blood mtDNA-CN in PD; effect strongest in substantia nigra pars compacta[23]Moderate
npj Parkinson's Dis 2024 PMC 11564539BloodLower mtDNA-CN in PD linked to immune cell shifts (↓ lymphocytes, ↑ NLR)[24]Moderate
Movement Disorders 2025 PMID 39760477BloodLower mtDNA-CN → worse UPDRS-III + higher risk of PDD in prospective follow-up[25]Moderate
Take-HomeBlood mtDNA-CN is most consistently replicated biomarker (Moderate). In PD, lower mtDNA-CN predicts future PDD. Sex-stratified analysis essential.

4Circulating Cell-Free mtDNA (ccf-mtDNA)

Critical ParadigmCSF ccf-mtDNA is REDUCED in AD and PD (counterintuitive). Plasma ccf-mtDNA shows mixed results. CSF reflects CNS mitochondrial output; plasma mixes multi-organ sources. Never interpret CSF and plasma ccf-mtDNA interchangeably.

4.1 CSF ccf-mtDNA — AD

GRADE 證據確定性：⊕⊕⊕⊝ Moderate Consistent CSF reduction; preclinical detection confirmed

StudyStageKey FindingGRADE
Podlesniy et al. 2013 PMID 24126837Preclinical ADLow CSF mtDNA in biomarker-confirmed asymptomatic individuals — before cognitive symptoms[43]Moderate
CSF mtDNA in AD continuumMCI-AD → dementiaProgressive ↓ CSF ccf-mtDNA across AD stages; mirrors cognitive decline[42]Low
Salivary mtDNA in CN (2025)Preclinical↓ Salivary mtDNA correlates with plasma Aβ42/40 and p-tau217[30]Very Low

4.2 CSF ccf-mtDNA — PD

GRADE 證據確定性：⊕⊝⊝⊝ Low-Moderate Consistent reduction; levodopa is critical confound

StudyFindingGRADE
Lowes et al. 2015 PMID 26343811Reduced CSF ccf-mtDNA in early-stage PD vs controls[26]Moderate
Mol Neurodegeneration 2020 PMID 32070373ccf-mtDNA significantly influenced by treatment: levodopa/DA-agonists → further reduction[27]Moderate
Sci Rep 2020 nature.com ↗Reduced ccf-mtDNA across PD, AD, and MS — pan-neurodegeneration marker[28]Low
Treatment ConfoundLevodopa independently reduces CSF ccf-mtDNA (PMID 32070373). Any PD study must stratify by treatment status.
重點整理CSF ccf-mtDNA 在 AD 和 PD 中均「下降」，且在 preclinical AD 即可偵測。血漿 ccf-mtDNA 結果不一致。兩者代表不同生物機制，不可互換解讀。

5mtDNA Methylation (D-Loop Epigenetics)

GRADE 證據確定性：⊕⊕⊝⊝ Low Novel layer; limited sample sizes; no large prospective studies

StudySampleKey FindingGRADE
D-Loop methylation in MCI (2022)Peripheral blood↑ D-loop CpG methylation in MCI vs CN — earliest epigenetic mitochondrial signal[21]Low
Longitudinal D-loop + CN in AD (2026)Peripheral bloodLongitudinal ↑ D-loop methylation + ↓ mtDNA-CN tracks AD staging[49]Low
ML model using D-loop methylcytosines (2025) PMC 11714325BloodD-loop methylcytosine + ML predicts MCI → AD conversion; AUC = 0.85[57]Low
Take-HomeD-loop CpG hypermethylation → suppressed TFAM binding → ↓ mtDNA-CN: trackable epigenetic-quantity axis from peripheral blood. ML model AUC 0.85 is the most clinically promising application.

6PBMC Mitochondrial Dysfunction

GRADE 證據確定性：⊕⊕⊝⊝ Low Small pilot studies; no standardised assay protocol

StudyMethodDiseaseKey FindingGRADE
Blood-based bioenergetic profiling (2022)Seahorse XFADReduced spare respiratory capacity and basal OCR in AD PBMC[31]Low
T-cell mitoproteomics (2025)LC-MS/MSADAltered Complex I/III subunits in T cells; peripheral proteome mirrors CNS pathology[32]Very Low
MFI (Hauger et al. 2025) PMC 12745175Flow cytometryADMFI = log[(MitoTracker × TMRE)/(MitoSox × Annexin V)]; outperforms SIMOA Aβ, pTau181, GFAP, NfL for CN vs AD discrimination[56]Low
MFI as Methodological TemplateMFI (Hauger et al. PMC 12745175) integrates membrane potential, mass, superoxide, and apoptosis into a single flow cytometry index — directly applicable as Aim 3 assay.

7CoQ10 as Co-Biomarker

GRADE 證據確定性：⊕⊕⊝⊝ Low SR evidence for AD; single RCT in MCI; heterogeneous endpoints

StudyDiseaseKey FindingGRADE
CoQ10 and Dementia SRAD/dementiaPlasma CoQ10 consistently lower in AD across multiple studies[39]Moderate
CoQ10 + mito dysfunction AD (2024)ADCoQ10 deficiency → Complex I/III dysfunction → ↑ ROS → ↑ 8-OHdG[34]Low
Ubiquinol in MCI RCT (2021)MCIUbiquinol 200 mg/day improved cerebral vasoreactivity and reduced CRP/IL-6 — small RCT[38]Low
MitoQ in PD — Negative TrialMitoQ showed no clinical benefit in Phase II PD RCT. Supports the early intervention window hypothesis.

8Mechanistic Framework

The diagram integrates all biomarker families into a unified model across the aging–neurodegeneration continuum. Mechanistic supports: [3][4][40][52].

Normal Aging  ·  正常老化
↓
Progressive mtDNA oxidative damage
粒線體 DNA 氧化損傷持續累積（hydroxyl radical + guanine → 8-OHdG）
↑ 8-OHdGUrine · Plasma · CSF
↓
D-loop CpG hypermethylation + mtDNA deletions accumulate
D-loop 高甲基化 → TFAM 結合受抑；缺失在 D-loop 及 ND 基因區累積
↓
↓ Mitochondrial biogenesis  (PGC-1α · NRF1 · TFAM)
粒線體生物合成減少，每細胞粒線體數量下降
↓ mtDNA-CNBlood · Brain
↓
Bioenergetic failure  ·  能量代謝衰竭
↓ ATP  ·  ↓ Δψm  ·  ↓ CoQ10  ·  ↓ SRC in PBMC
↓
AD Pathway
Aβ ↔ mitochondria（互相強化）
↑ ROS → ↑ 8-OHdG（vicious cycle）
tau hyperphosphorylation
PD Pathway
α-syn aggregation at mitochondria
PINK1 / Parkin impairment → ↓ mitophagy
DA cell death → further mtDNA damage
↓  共同下游機制 ↓
cGAS-STING activation
Cytosolic damaged mtDNA → cGAS → STING → IRF3 / NF-κB → TNF-α · IL-6 · IL-1β · IFN-β
↓
Neuroinflammation → Synaptic loss → Neuronal death
神經炎症 → 突觸喪失 → 神經元死亡（AD / PD 共用下游通路）
Biofluid Readouts  ·  生物標記讀出值
↑ 8-OHdGUrine / Plasma / CSF
↓ mtDNA-CNBlood
↓ CSF ccf-mtDNACSF（↓ 反直覺）
↑ D-loop methylationBlood
↓ CoQ10Plasma
↓ MFIPBMC flow cytometry

cGAS-STING activated by damaged mtDNA drives spread of PD-like pathology[3]; mitochondria-derived EVs package mtDNA for trans-synaptic propagation[52]; mitohormesis overwhelmed in neurodegeneration[4]; proteinopathy (Aβ, α-syn, tau) directly impairs mitochondria — bidirectional vicious cycle[40].

重點整理8-OHdG ↑ 與 mtDNA-CN ↓ / CSF ccf-mtDNA ↓ 代表同一病理軸的不同面向。cGAS-STING 是連接粒線體損傷與神經炎症的關鍵分子橋梁，在 AD 和 PD 中共用。

9Cross-Disease Comparison Summary

MarkerSpecimenAgingMCIADPDGRADEKey Notes
8-OHdGUrine↑ age↑↑↑↑↑ModerateSR&MA support; MSA also ↑
8-OHdGPlasma↑ age↑↑↑↑ModerateLiu 2016 confirmed
8-OHdGCSF↑ age↑↑↑↑↑LowMost CNS-specific; invasive
mtDNA-CNBlood↓ age↓↓↓↓↓ModerateSex effect in AD; 13/15 studies consistent
ccf-mtDNACSF↓?↓↓↓↓↓Moderate↓ direction (counterintuitive); treatment confound in PD
ccf-mtDNAPlasma↑?—↑/——LowInconsistent
D-loop methylationBlood↑↑↑↑—LowML AUC 0.85; no PD longitudinal data
CoQ10Plasma↓↓↓↓↓LowSR evidence; therapeutic candidate in MCI
Multi-Marker Panel Recommendation建議整合型組合：血漿 8-OHdG（氧化損傷）+ 血液 mtDNA-CN（粒線體含量）+ CSF ccf-mtDNA（若可取得）+ p-tau217（tau 病理）。

10Limitations of Current Literature

IssueDetailImpact
8-OHdG assay inconsistencyELISA cross-reacts with guanosine derivatives; LC-MS/MS more specific; no universal standardCross-study comparison unreliable
mtDNA-CN platform variationqPCR reference gene choice causes 2–5× variation; platelet count (high mtDNA, no nuclear DNA) is major uncontrolled confounderSystematic over/underestimation
Treatment confoundingChEI ↑ mtDNA-CN[14]; levodopa ↓ CSF ccf-mtDNA[27]; rarely stratifiedSystematic cross-study bias
Ethnic homogeneityMajority European White or Japanese; limited Asian validationExternal validity to Taiwanese cohorts uncertain
Cross-sectional majorityCannot establish temporal precedence; reverse causation unresolvedGRADE capped at Moderate
Critical GapNo single study has simultaneously measured 8-OHdG + ccf-mtDNA + mtDNA-CN + CoQ10 + ATN biomarkers in the same well-characterised cohort.

11Unresolved / Key Unanswerable Questions

Unresolved Question 1
What is the temporal sequence — 8-OHdG elevation or mtDNA-CN decline first?
CSF ccf-mtDNA reduced in biomarker-confirmed preclinical AD (Podlesniy 2013[43]). Plasma 8-OHdG preclinical timing lacks large-scale data.
No prospective cohort tracking 8-OHdG + mtDNA-CN + ccf-mtDNA + ATN from normality through MCI conversion.
Unresolved Question 2
Can 8-OHdG and mtDNA-CN reliably differentiate AD from PD, DLB, MSA, or PSP at individual level?
Both AD and PD show 8-OHdG ↑ and mtDNA-CN ↓. MSA urinary 8-OHdG also elevated[15]. No direct head-to-head multi-disease studies.
Published AUC values almost all AD vs controls or PD vs controls — not cross-disease.
Unresolved Question 3
Should a 'M' (Mitochondrial) axis be added to the ATN framework?
Alzheimer's Res Ther 2024 shows mtDNA-CN correlates with CSF Aβ42/40, tau, NfL but suggests independent information[46].
Requires N > 500 prospective cohort with ATN + mtDNA-CN + incremental value analysis.
Unresolved Question 4
Why is the mtDNA-CN/AD association stronger in females?
Alzheimer's Res Ther 2024 — sex-specific association in females[46]. Mechanism completely unexplored.
Requires sex-stratified, hormone-measured cohort with mitochondrial biogenesis pathway assays.
Unresolved Question 5
What are the normal reference ranges for 8-OHdG and mtDNA-CN in Taiwanese/Han Chinese elderly?
All normative data from European White or Japanese cohorts. APOE4 frequency lower in East Asians (~10% vs ~15%).
Foundational study needed: prospective Taiwan cohort (N ≥ 300, age 60–80+, sex-stratified).

12Currently Ongoing Related Trials

Trial / NCTStatusRelevance
CSF Mitochondrial Biomarkers in Stroke & AD NCT07600996 ↗🌟 Recruiting 2026/03–08Direct: simultaneous CSF mitochondrial biomarker collection in AD; Capital Medical University
PPMI NCT01141023 ↗Ongoing longitudinalLargest PD biomarker resource; active mtDNA sub-studies
MFI Validation (Hauger 2025) PMC 12745175Pilot complete; external validation ongoing★ MFI outperformed SIMOA plasma biomarkers for CN vs AD[56]
mtDNA Methylcytosines ML PMC 11714325Pilot complete; multicenter validation needed★ Blood D-loop ML → MCI-to-AD AUC 0.85; requires Asian validation[57]
NCT07600996Sponsor: Capital Medical University | Start: March 2026 | Completion: August 2026 | Method: CSF mitochondrial biomarkers by flow cytometry | Status: recruiting (verified June 2026). ClinicalTrials.gov ↗

13Future Research Directions

DirectionPriorityFeasibilityKey Output
Taiwan normative database: mtDNA-CN + urinary 8-OHdG in Taiwanese elderly ≥60yo★★★High — single-centerFoundational; publishable standalone
Longitudinal MCI → AD conversion: p-tau217+ MCI, track 8-OHdG + mtDNA-CN ×2–3 years★★★Moderate (2–3yr)First prospective oxidative biomarker trajectory predicting AD conversion
Multi-biomarker panel: 8-OHdG + mtDNA-CN + ccf-mtDNA + CoQ10 + MFI in ATN-confirmed cohort★★★Moderate — multicenterEstablishes incremental value; defines optimal panel
cGAS-STING validation in human CSF/PBMC★★☆ModerateMeasure STING, IRF3, IFN-β in CSF/PBMC; correlate with ccf-mtDNA
MFI external validation in Asian cohort (N ≥ 150)★☆☆2–3 yearsReproduce Hauger 2025 in Taiwanese MCI/AD
AI/ML multi-biomarker model with SHAP explainability★☆☆1–2 years post-data8-OHdG + mtDNA-CN + D-loop methylation + MFI
Grant Writing (Aim 1/2/3 Framework)Aim 1 = Taiwan normative reference database; Aim 2 = 縱向 MCI → AD 追蹤，p-tau217 確認入組，8-OHdG + mtDNA-CN 預測轉換率; Aim 3 = PBMC Seahorse + MFI 平台作為機制性驗證。

14References

42 publications included. Local Drive ↗ = Google Drive @ 8-OhDG folder (本地版可點擊開啟資料夾). Web = PubMed/PMC/journal link verified.

  1. Korkmaz A et al. Detection of 8-OHdG as a diagnostic biomarker. J Lab Precis Med. 2019. Full text ↗Web
  2. Valavanidis A et al. 8-hydroxy-2′-deoxyguanosine: A critical biomarker of oxidative stress. J Environ Sci Health C. 2009. PMID 19412858Web
  3. Sliter D et al. Mitochondrial DNA damage triggers spread of Parkinson's disease-like pathology. Mol Psychiatry. 2023. Local Drive
  4. Roles of mitochondrial stress responses and mitohormesis in neurodegenerative disorders. Int J Mol Sci. 2026. Local Drive
  5. Graille M et al. Urinary 8-OHdG as a biomarker for oxidative stress: SR and meta-analysis. Int J Mol Sci. 2020. PMID 32428208 PMC 7313038Web
  6. Oxidative Stress and the Aging Brain. NCBI Bookshelf. NBK3869 ↗Web
  7. Chen K et al. Urinary 8-oxoGsn as a potential biomarker of aging. Aging (Albany NY). 2018. PMC 5835306Web
  8. Association of mtDNA Copy Number With Brain MRI Markers and Cognitive Function: meta-analysis. Local Drive
  9. Liu Z et al. Altered plasma 8-OHdG and antioxidant capacity in Alzheimer's disease. Arch Med Res. 2016. PMC 4913710 Local Drive
  10. Telomere length and 8-OHdG as markers for early prediction of Alzheimer disease. Local Drive
  11. Butterfield DA et al. A review of oxidative stress products and related genes in early Alzheimer's disease. Antioxidants. 2021. PMC 8543250Web
  12. Oxidative stress and inflammation associated with physical frailty in Alzheimer's disease. Local Drive
  13. Antioxidant Defence, Oxidative Stress and Damage in Saliva, Plasma and Erythrocytes of Dementia Patients. Local Drive
  14. Śliwińska S et al. Oxidative stress biomarkers and mtDNA copy number associated with APOE4 and ChEI therapy. J Clin Med. 2022. PMC 8750673 Local Drive
  15. Kikuchi A et al. Urinary 8-hydroxydeoxyguanosine as a biomarker for progression of Parkinson disease. Neurology. 2002. Neurology ↗ (Classic)Web
  16. Urinary 8-OHdG correlates with hallucinations in Parkinson's disease. Parkinsonism Relat Disord. 2010. ScienceDirect ↗Web
  17. Rani V et al. Oxidative stress-related biomarkers in Parkinson's disease: SR and meta-analysis. Oxid Med Cell Longev. 2019. PMC 6420691Web
  18. Oxidative stress in Parkinson's disease: SR and meta-analysis. Front Aging Neurosci. 2018. PMC 6041404Web
  19. [Reference 19 merged with Ref 8 — mtDNA-CN meta-analysis]
  20. Biological and translational attributes of mtDNA copy number: laboratory to clinical relevance. 2025. Local Drive
  21. Increase in Mitochondrial D-Loop Region Methylation in Mild Cognitive Impairment. 2022. Local Drive
  22. Mitochondrial blood-based and genetic markers in MCI and remitted major depressive disorder. 2024. Local Drive
  23. Bose A, Bhatt DL. Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease. Neurobiol Dis. 2016. PMID 26639155 PMC 4759605Web
  24. Peripheral immune cell abundance links blood mtDNA copy number and Parkinson's disease. npj Parkinsons Dis. 2024. PMC 11564539 Local Drive
  25. Jo S et al. Mitochondrial DNA copy number as prognostic biomarker in Parkinson's disease. Mov Disord. 2025. PMID 39760477Web
  26. Lowes H et al. Reduced CSF mitochondrial DNA in early-stage Parkinson's disease. Mov Disord. 2015. PMID 26343811Web
  27. Lowes H et al. Circulating cell-free mtDNA levels in Parkinson's disease are influenced by treatment. Mol Neurodegener. 2020. PMID 32070373Web
  28. Post-mortem ventricular CSF cell-free mtDNA in neurodegenerative disease. Sci Rep. 2020. nature.com ↗Web
  29. CSF mitochondrial DNA as biomarker of body composition and energy metabolism in Parkinson's disease. 2025. Local Drive
  30. Salivary mitochondrial DNA associated with Alzheimer's disease biomarkers in cognitively normal adults. 2025. Local Drive
  31. Blood-based bioenergetic profiling reveals mitochondrial function differences. 2022. Local Drive
  32. Proteomic signatures and mitochondrial dysfunctions in peripheral T cells in Alzheimer's disease. 2025. Local Drive
  33. Mitochondrial dysfunction in PBMC of individuals with mild cognitive impairment. 2026. Local Drive
  34. CoQ10 and mitochondrial dysfunction in Alzheimer's disease. 2024. Local Drive
  35. Coenzyme Q10 and cognition: a review. 2025. Local Drive
  36. CoQ10 levels associated with cognitive functioning and executive function in older adults. 2023. Local Drive
  37. CoQ10 status, serum amyloid-β, and tau protein in dementia. 2022. Local Drive
  38. Ubiquinol supplementation improves cerebral vasoreactivity and ameliorates inflammation in MCI. 2021. Local Drive
  39. Coenzyme Q10 and dementia: a systematic review. Local Drive
  40. Bhatt S et al. Proteinopathy, oxidative stress and mitochondrial dysfunction in AD and PD. Prog Neurobiol. 2017. Local Drive
  41. ccf-mtDNA as a potential link between the brain and immune system in neuro-immunological disorders. Local Drive
  42. Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. Local Drive
  43. Podlesniy P et al. Low CSF mtDNA concentration in preclinical Alzheimer disease. Ann Neurol. 2013. PMID 24126837 Local Drive
  44. CSF mitochondrial DNA in rapid and slow progressive forms of Alzheimer's disease. Local Drive
  45. Correa JD et al. Oxidative stress and inflammatory metabolites with Alzheimer's disease CSF biomarkers in MCI. Alzheimers Res Ther. 2024. PMC 11287840Web
  46. Blood-derived mtDNA copy number associated with Alzheimer disease and biomarkers. Alzheimers Res Ther. 2024. doi ↗Web
  47. Oxidative stress biomarkers as preclinical markers of MCI: impact of age and sex. 2025. Local Drive
  48. Characterization of mitochondrial DNA methylation of Alzheimer's disease in plasma cfDNA. Local Drive
  49. Longitudinal D-loop methylation and mtDNA copy number in peripheral blood: epigenetic signatures of AD. 2026. Local Drive
  50. Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer's disease brain. Local Drive
  51. Circulating cell free DNA and DNA double-strand breakage in Alzheimer's disease. 2024. Local Drive
  52. Mitochondria extracellular vesicles in CNS disorders. Local Drive
  53. Mitochondrial DNA (mtDNA) as fluid biomarker in neurodegenerative disorders: SR. 2025. Local Drive
  54. Multipronged diagnostic and therapeutic strategies for Alzheimer's disease. 2025. Local Drive
  55. Immunological evaluation of Alzheimer's disease based on mitochondrial DNA indicators. Local Drive
  56. Hauger LE et al. A blood-based mitochondrial functional index biomarker for Alzheimer's disease. Alzheimers Dement. 2025. PMC 12745175Web
  57. mtDNA methylcytosines as blood-based biomarkers: ML model for AD dementia prognosis at MCI stage. Alzheimers Dement. 2025. PMC 11714325Web
  58. Probing diagnostic values of plasma cf-nDNA and cf-mtDNA for Parkinson's disease and MSA. Front Neurosci. 2024. doi ↗Web
  59. A blood-based marker of mitochondrial DNA damage in Parkinson's disease. Sci Transl Med. doi ↗Web
  60. Circulating cell-free DNA in precision neurology for AD. 2024. PMC 11595805Web